ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Research ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (R9Z) on Bullrun: market cap EUR 175.25M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerR9Z
- ExchangeF
- CountryChina
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 175.25M
- Financial periodFY2025
- RevenueCNY 154.29M
- Revenue growth108.1%
- Net income-CNY 218.58M
- Free cash flow-CNY 203.90M
- Gross margin99.3%
Valuation Snapshot
latest market cap is EUR 175.25M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CNY 154.29M | -CNY 218.58M | -CNY 203.90M | 99.3% | -0.53 | CNY 679.56M | CNY 228.03M | CNY 791.44M |
| FY2024 | CNY 74.15M | -CNY 315.86M | -CNY 138.44M | n/a | -0.84 | CNY 477.60M | CNY 136.36M | CNY 678.90M |
| FY2023 | CNY 386.00K | -CNY 379.46M | -CNY 370.25M | n/a | -1.05 | CNY 306.98M | CNY 74.77M | CNY 748.29M |
| FY2022 | CNY 538.00K | -CNY 402.89M | -CNY 261.93M | n/a | -1.08 | CNY 635.21M | CNY 14.62M | CNY 779.22M |
| FY2021 | CNY 5.07M | -CNY 732.95M | -CNY 315.79M | n/a | -1.96 | CNY 668.33M | CNY 18.54M | -CNY 1.60B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-15 | EUR 175.25M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc., a biotechnology company, engages in the research and development of immuno-oncology therapies in China and the United States. The company's core product candidate is IMM01, which is in Phase Ib/IIa clinical trial to evaluate the combination with bortezomib and dexamethasone for the treatment of multiple myeloma;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is ImmuneOnco Biopharmaceuticals (Shanghai) Inc.'s market cap?
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.'s market capitalization is EUR 175.25M.
What does ImmuneOnco Biopharmaceuticals (Shanghai) Inc. do?
ImmuneOnco Biopharmaceuticals (Shanghai) Inc., a biotechnology company, engages in the research and development of immuno-oncology therapies in China and the United States.